M&A Deal Summary |
|
---|---|
Date | 2012-08-01 |
Target | Pall - Transfusion Medicine Business |
Sector | Medical Products |
Buyer(s) | Haemonetics |
Sellers(s) | Pall |
Deal Type | Divestiture |
Deal Value | 551M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1971 |
Sector | Medical Products |
Employees | 2,708 |
Revenue | 1.3B USD (2024) |
Haemonetics is a healthcare company dedicated to providing innovative blood management solutions for customers. The company devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients worldwide. Haemonetics was founded in 1971 and is based in Boston, Massachusetts.
DEAL STATS | # |
---|---|
Overall | 10 of 15 |
Sector (Medical Products) | 4 of 8 |
Type (Divestiture) | 1 of 1 |
Country (United States) | 9 of 12 |
Year (2012) | 1 of 1 |
Size (of disclosed) | 1 of 10 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2010-02-01 |
Global Med Technologies
El Dorado Hills, California, United States Global Med Technologies, Inc. is a healthcare information technology company which markets a breadth of software solutions and services that span the blood supply continuum, from blood collection to the hospital transfusion center to the patient care environment. |
Buy | $60M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2013-05-01 |
Hemerus Medical
St. Paul, Minnesota, United States Hemerus Medical LLC is a technologies for the collection of whole blood, and processing and storage of blood components. Hemerus has completed Phase 3 clinical trials and has submitted a New Drug Application to the FDA for its unique, patented SOLX® whole blood collection system. |
Buy | $27M |
Category | Company |
---|---|
Founded | 1946 |
Sector | Manufacturing |
Employees | 10,400 |
Revenue | 2.8B USD (2014) |
Pall Corp. is a provider of filtration, separation and purification products to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry.
DEAL STATS | # |
---|---|
Overall | 1 of 3 |
Sector (Medical Products) | 1 of 1 |
Type (Divestiture) | 1 of 3 |
Country (United States) | 1 of 2 |
Year (2012) | 1 of 1 |
Size (of disclosed) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2011-12-19 |
ForteBio
Menlo Park, California, United States ForteBio is a wholly-owned subsidiary of Pall Corp. and a division of Pall Life Sciences. ForteBio develops analytical systems that enable real-time analysis of biomolecular interactions (protein quantification and characterization of protein-protein interactions, etc.) in micro-volume sample sizes, providing information on affinity, kinetics, and concentration. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2014-02-20 |
ATMI- LifeSciences Business
United States ATMI- LifeSciences Business is a technology provider in the field of single use bioprocess systems and consumables for the pharmaceutical and biopharmaceutical industries. |
Buy | $185M |